Alkermes PLC has received $-0.19 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.21 while the top line estimate is $-0.17 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 36.67%.
Dublin 4 based Alkermes PLC Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Feb 23, 2017.
In the last quarter, Alkermes PLC reported Annual Earnings of $-0.25. Based on the filings, last years Annual Earnings was, $-1.01. In the last Quarter, ALKS reported a surprise Earnings per Share of 0% . The consensus estimate for current quarter is $-0.19 and for the current fiscal year, the estimate is $-0.93. For the Next fiscal year, the estimate is $-0.59 based on the consensus.
Alkermes plc (NASDAQ:ALKS) : On Tuesday heightened volatility was witnessed in Alkermes plc (NASDAQ:ALKS) which led to swings in the share price. The stock opened for trading at $51.98 and hit $54.3 on the upside , eventually ending the session at $54.11, with a gain of 3.54% or 1.85 points. The heightened volatility saw the trading volume jump to 1,329,144 shares. The 52-week high of the share price is $60.74 and the company has a market cap of $8,223 million. The 52-week low of the share price is at $27.14 .
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.